Biocon inches closer for Europe approval of biosimilar Trastuzumab
newsdepo.com
Trastuzumab, the biosimilar version of Swiss drug maker Rocheâs Herceptin had brand sales of $1.9 billion in Europe for the 12 months ended July 31, according to IQVIA.Biocon inches closer for Europe approval of biosimilar Trastuzumab
Trastuzumab, the biosimilar version of Swiss drug maker Rocheâs Herceptin had brand sales of $1.9 billion in Europe for the 12 months ended July 31, according to IQVIA. Read more